Clinical Trial Sites
Investigator sites and clinical research units — running trials to Good Clinical Practice, protecting subjects, and generating the source data a submission is built on.
Clinical trial sites — hospitals, dedicated research units, and investigator offices — are where a study actually meets patients. They enroll and protect subjects, execute the protocol, and generate the source data on which the entire submission ultimately rests. The credibility of a marketing application depends on what happens, and what is recorded, at the site.
Sites operate to Good Clinical Practice (ICH E6(R3), building on E8(R1) study design), under FDA 21 CFR Parts 312, 50, and 56 and, in the EU, the Clinical Trials Regulation (536/2014). Subject safety runs through informed consent and IRB/ethics-committee oversight, and adverse events feed pharmacovigilance under ICH E2A and EU GVP. Source data and electronic systems carry ALCOA+ and 21 CFR Part 11 expectations.
The site works under the sponsor and its monitors but is led by a principal investigator who is personally accountable for the conduct of the trial and the safety of subjects. The sponsor provides the protocol and performs risk-based monitoring; the ethics committee/IRB safeguards subjects; and the investigator ensures the protocol is followed and the data are attributable and accurate. Accountability is shared, but subject protection sits squarely with the site.
Subject safety & informed consent
Valid, documented informed consent and IRB/ethics oversight — the ethical foundation without which no data are usable.
Protocol adherence
Following the approved protocol and documenting any deviation, so the data mean what the analysis assumes they mean.
Source data & ALCOA+
Attributable, legible, contemporaneous, original, accurate source records — the evidence a monitor and inspector reconstruct the trial from.
Safety reporting
Timely identification and reporting of adverse events to the sponsor and, as required, to authorities under the expedited-reporting clock.
- ›Informed-consent or IRB/ethics failures that invalidate a subject’s data
- ›Protocol deviations that go undocumented or unexplained
- ›Source-data gaps that prevent reconstruction of what happened at the visit
- ›Adverse events identified or reported late against the required timeline
Derived from the 12 standards SPEQ decodes for this sector.
Intelligence for Clinical Trial Sites
The enforcement actions, guidance, and quality signals that shape sponsor–provider oversight — curated for Clinical Trial Sites and delivered free each week.